Short Interest in MariMed Inc. (OTCMKTS:MRMD) Expands By 271.6%

MariMed Inc. (OTCMKTS:MRMD) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 37,428 shares, an increase of 271.6% from the November 30th total of 10,071 shares. Based on an average daily volume of 2,872,286 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are short sold. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 2,872,286 shares, the days-to-cover ratio is currently 0.0 days.

MariMed Price Performance

Shares of MariMed stock traded up $0.00 during trading on Friday, hitting $0.10. The stock had a trading volume of 410,026 shares, compared to its average volume of 1,887,970. MariMed has a 12 month low of $0.07 and a 12 month high of $0.23. The business’s 50-day moving average is $0.10 and its 200 day moving average is $0.11. The company has a current ratio of 1.06, a quick ratio of 0.35 and a debt-to-equity ratio of 1.34. The firm has a market cap of $38.73 million, a price-to-earnings ratio of -2.45 and a beta of 1.02.

MariMed (OTCMKTS:MRMD) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). MariMed had a negative return on equity of 14.67% and a negative net margin of 11.36%.The firm had revenue of $40.76 million for the quarter, compared to analysts’ expectations of $42.15 million.

Analyst Ratings Changes

A number of analysts have commented on the stock. Zacks Research cut shares of MariMed from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 11th. Ventum Cap Mkts cut shares of MariMed from a “strong-buy” rating to a “hold” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, MariMed has a consensus rating of “Hold”.

MariMed Company Profile

MariMed Inc is a multi?state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult?use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre?rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.